Connect public, paid and private patent data with Google Patents Public Datasets

Topical analgesic preparation and method of using

Download PDF

Info

Publication number
US3880996A
US3880996A US44976574A US3880996A US 3880996 A US3880996 A US 3880996A US 44976574 A US44976574 A US 44976574A US 3880996 A US3880996 A US 3880996A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
analgesic
preparation
pain
salicylate
invention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Arthur I Fisher
Original Assignee
Arthur I Fisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

An analgesic composition for the symptomatic relief of localized pain of musculo-skeletal etiology is adapted for topical application over affected areas and includes an analgesic, e.g., a salicylate, a local counter-irritant, and an organopolysiloxane.

Description

United States Patent Fisher Apr. 29, 1975 TOPICAL ANALGESIC PREPARATION AND Handbook of Non-Prescription Drugs, (1967), pp.

METHOD OF USING 63-66.

[76] Inventor: Arthur I. Fisher, Box 228 Herod Point Rd., Wading River, NY. Primary Examiner-Stanley J. Friedman l 1792 Attorney, Agent, or FirmNatter & Natter, Esqs.

[22] Filed: Mar. 11, 1974 [2]] Appl. No.: 449,765 [57] ABSTRACT An analgesic composition for the symptomatic relief [22:] lJScCll 424/1846, 424/358 of localized pain of musculoskeletal etiology is f i f gg adapted for topical application over affected areas and l o earc l 8 3 includes an analgesic, e.g., a salicylate, a local coun- References Cited ter-irritant, and an organopolysiloxane.

OTHER PUBLICATIONS Merck Index, 7th Ed., (1960), p. 934.

8 Claims, N0 Drawings TOPICAL ANALGESIC PREPARATION AND METHOD OF USING BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates generally to topically applied analgesic preparations.

2. Brief Description of the Prior Art Local analgesics have been commonly used for the symptomatic relief of musculo-skeletal pain. Generally, these analgesic preparations have been available in the form of lotions, liniments and ointments for topical application and usually included an analgesic and a rubefacient, such as camphor, menthol, etc.

Although prior local analgesics have, in some instances, resulted in beneficial pain mitigation for mildly inflamed arthritic joints, the use of such preparations has provided but limited and short-lived relief. With most local analgesics, it is believed that the major factor attributable to their but limited efficacy was the inability to promote sufficient percutaneous absorption of the analgesic. A substantial factor in whatever pain relief was achieved is believed to have been the rubefacient which provided the source of counter-irritation resulting in localized heat sensation and concommitant psychological diversion or through the utilization of local anesthetics such as chloroform.

SUMMARY OF THE INVENTION An analgesic composition for local application includes a salicylate analgesic, e.g., glycol monosalicylate, a rubefacient, e.g., capsicum oleoresin, and a minor amount of organopolysiloxane (silicone). The composition can be employed with a suitable carrier or vehicle such as lanolin. The synergistic action of the composition results in enhanced salicylate absorption and alleviation of musculo-skeletal pain.

From the foregoing, it should be appreciated that it is an object of the present invention to provide an analgesic preparation of the general character described which is not subject to the disadvantages of preparations heretofore used.

It is a further object of the present invention to provide an analgesic preparation of the general character described which is adapted to provide effective alleviation of localized musculo-skeletal pain.

A further object of the present invention is to provide an analgesic preparation of the general character described having enhanced percutaneous analgesic absorption.

Another object of the present invention is to provide an analgesic preparation of the general character described which is well suited for topical application to provide alleviation of localized pain, inflammation and edema associated with arthritic joints.

Yet another object of the invention is to provide an analgesic preparation of the general character described which includes an analgesic, a rubefacient, and an organopolysiloxane in a suitable carrier for topical application.

Other objects and advantages of the invention in part will obvious and in part will be pointed out hereinafter.

With these ends in view, the invention resides in certain new and unique preparations and the synergistic action of the components thereof by which the said objects and certain other objects are hereinafter attained, all as fully described and the scope of which is more particularly pointed out and indicated in the appended claims.

DESCRIPTION OF THE PREFERRED EMBODIMENTS The analgesic preparation of the present invention comprises several of the basic constituents of presently known commercial topical preparations for use in musculo-skeletal pain alleviation to which a quantity of an organopolysiloxane is added. It was unexpectedly discovered, in accordance with the present invention, that the presence of the organopolysiloxane greatly enhanced the ability of the prior preparations to alleviate such pain and relieve the underlying irritation. Especially with instances of arthritic associated discomforts, the presence of the organopolysiloxane provides an analgesic preparation of increased efficacy, the use of which has achieved a marked improvement in joint mobility.

As is well known, organopolysiloxanes, popularly called silicones, are a group of compounds having the structural formula:

R R R I l l R-Si-O -Si-O -Si-R l l l R R R wherein R represents an organic radical such as an alkyl, aryl, alkaryl, aralkyl, including benzyl, phenyl, methyl, tolyl and the like. Enhanced results are obtained with and accordingly it is preferred to employ C,C dialkylpolysiloxanes such as dipropylpolysiloxane, dihexylpolysiloxane and the like. The length n of the polymer chain can be between 0 to 2,000 and determines the viscosity of the liquid and preferred results are obtained wherein the organopolysiloxane viscosity ranges between 50 200 centistokes. Suitable polysiloxanes are disclosed in US. Pat. Nos. 3,392,040 and 3,378,440, the contents of which are expressly incorporated herein.

Among the suitable organopolysiloxanes for use in the present invention are dimethylpolysiloxane liquids which can be generally represented as follows:

CH3 CH3 CH3 l l CH -Si-O -Si-O -Si-CH CH CH n CH In accordance with the present invention, a conventional analgesic ointment base comprising an analgesic salicylate such as methyl salicylate, glycol monosalicylate, trithamalamine salicylate and the like, and a rubefacient, such as capsicum oleoresin, camphor, chloroform, menthol, allyl isothiocyanate and the like, is formulated as an ointment, for example employing a conventional carrier or vehicle, such as a greaseless vehicle. In the analgesic ointment base, the rubefacients desirably provide a local vasodilation effect which may be further enhanced with such typical local vasodilators as methacholine chloride, histamine dihydrochloride and the like. Analgesic ointments of the foregoing nature ire commercially available and, as mentioned hereto- "ore, have met with but limited results. It is believed vhat mitigation of referred pain through these local anilgesics was ideally provided by percutaneous salicyate absorption which was designed to be facilitated .hrough the use of the rubefacient and/or vasodilator.

The analgesic composition of the present invention is achieved by the addition of an organopolysiloxane to he foregoing analgesic ointment base. It has been esablished that the admixture of the analgesic base com- )osition and the organopolysiloxane provides enianced effectiveness that can not be achieved from the tse of the individual constituents. For example, the :omposition of thepresent invention has provided a iefinite increase in pain relief of discomforts associated with arthritic symptoms as well as a marked reduction n edema and greater joint mobility as compared with 'outine use of the analgesic ointment base not containng the organopolysiloxane.

In general, an effective amount of the organopolysioxane is employed. Usually it is preferred to employ a ninor amount by total weight of the preparation. lf imounts significantly less than about percent by otal weight of the preparation are employed, no signifcant improvements, as compared to the analgesic ointnent base, are obtained and the organopolysiloxane lcts primarily as an emollient. Little, if any, synergistic nteraction is obtained.

Employing organopolysiloxane in amounts greater han about 40 percent by total weight of the preparaion unduly decreases the viscosity of the ointment )reparation to render it generally unacceptable for topcal use and also renders the ointment difficult to fornulate, package and apply. Best results are generally )btained employing the organopolysiloxane from about .3 percent by total weight of the preparation.

The analgesic preparation of the present invention is 'ormulated according to conventional procedures too vell known to the art to specifically describe. Of :ourse, other conventional additives commonly em- )loyed in topical ointments, e.g. pigments, stabilizers, lntioxidants and the like, can also be added in convenional amounts.

1n the following examples are described several of the )referred embodiments of the invention in an exemilary manner. It should be understood, however, that he invention is not intended to be limited to these spe- :ific embodiments.

EXAMPLE 1 Quite satisfactory results have been obtained utilizng, as an analgesic ointment base, a conventional anal- ;esic ointment containing the following constituent in- ;redients: glycol monosalicylate (approximately 10 iercent), capsicum oleoresin, histamine dihydrochlor- 11c, and methyl nicotinate in a lanolin carrier or vehile. An example of such analgesic preparation is the 'intment sold under the trademark Infra-Rub by Vhitehall Laboratories, New York, NY.

Commencing with a base of 3.3 oz. of this commerially available preparation, 0.6 oz. of silicone dimethlpolysiloxane (L-45 Union Carbide 100 cts.) was dded and mixed. A paste composition of uniform conistency resulted. The preparation was topically applied 9 the skin over arthritic joints once daily. With routine pplication, a marked decrease in inflammation was oted along with greater joint mobility after approximately three days. Concordant results have been obtained with 0.5 oz. silicone dimethylpolysiloxane 1-45 Union Carbide cts.) added to 3.3 oz. of an identical base.

While the precise reasons for the decrease in inflammation, concommitant pain relief and improved joint mobility are unknown, it has been established that the addition of the organopolysiloxane to the commercially available ointment base does result in a marked increase in percutaneous analgesic absorption.

Experiments were performed to determine the percutaneous salicylate absorption levels of a preparation similar to that of Example 1, with a 25 percent organopolysiloxane content. One hind rat foot was immersed in a vial containing the commercial ointment base preparation and compared with similar immersions in a vial containing the preparation of Example 1. The test animals were placed in a metabolic cage, a 24 hour urine specimen was collected, urine volume recorded and salicylate level measured. The following table outlines the testing results:

Ointment Base lmmersion Timc (min.) 7: salicylate in Urine Ointment Base with 257r L-45 Silicone 100 cts.)

Immersion Timc (min.) 7( salicylate in Urine It was thus determined that a substantial increase in percutaneous salicylate absorption has been achieved with the analgesic preparation of the present invention as compared with the commercial analgesic ointment base.

EXAMPLE 2 An analgesic ointment base of the following formulation was prepared:

ANALGESIC OlNTMENT BASE Salicylamidc 371 Dipropylcne glycol salicylate 3'7? Methyl nicotinate 0.571 Histamine dihydrochloride 0.057: Capsicum oleorcsin 0.0571 Stcaryl alcohol 3.7367: Glyceryl monostearatc 2.337571 Stcaric acid 4.68% Petrolatum 9.36% Mineral oil 4.687: Methyl parahcn 0.093671 Propyl parahcn 0.09367: Tricthanolamine 0.4687: Sodium lauryl sulfate-20% 0.468% Water 0.8.

An analgesic ointment of this general nature is presently manufactured by Ambix Laboratories, Inc. of North Bergen, NJ.

Commencing with a base of 3.3 oz. of this analgesic ointment base, 0.6 oz. of silicone dimethylpolysiloxane (L45 Union Carbide l00 cts.) was added to provide an ointment of uniform consistency in accordance with the present invention.

The composition was applied to locally inflamed areas over arthritic joints once daily. As with the composition of Example 1, a marked decrease in swelling inflammation accompanied by a decrease in pain and discomfort associated with the arthritic areas was noted with routine local application after approximately three days.

EXAMPLE 3 An analgesic ointment comprising methyl salicylate and menthol in a lanolin base was utilized as the analgesic ointment base. This ointment is generally available and sold under the trademark Ben-Gay by Pfizer, Inc. of New York, N.Y. To a base of 3.0 oz. of this ointment. 0.6 oz. of silicone dimethylpolysiloxane (L-45 Union Carbide 100 cts.) was added. In accordance with the present invention, the polysiloxane was admixed with the base to provide a paste of uniform consistency.

The preparation was topically applied over arthritic joint areas once daily. As in the previous examples, cessation of pain, a marked decrease in inflammation and greater joint mobility were noted after approximately 3 days.

EXAMPLE 4 An analgesic ointment comprising methyl salicylate, glycol monosalicylate, menthol, camphor and allyl isothiocyanate in a carrier of petrolatum and lanolin was utilized as the analgesic ointment base. A commercially available analgesic of this nature is sold under the trademark Musterole by Schering Plough Corp. of Bloomfield, NJ. To a base of 3.3 oz. of this ointment, 0.6 oz. of silicone dimethylpolysiloxane (L-45 Union Carbide I00 cts.) was added. The preparation thus formulated was topically applied over arthritic joint areas once daily. As in the previous examples, cessation of pain, decrease in inflammation and greaterjoint mobility were noted after approximately 3 days.

Results similar to those obtained in the foregoing examples are obtainable when other C -C dialkylpolysiloxanes such as dipropylpolysiloxane, dihexylpolysiloxane and the like are employed.

While the precise reason for the decrease in pain and discomfort as well as the reduction in inflammation and improved joint mobility when utilizing the composition of the present invention is unknown, it has been established that the polysiloxane definitely enhances the percutaneous salicylate absorption as compared with prior analgesic ointments. This phenomenon might be attributed to the lubricity of the polysiloxane in facilitating percutaneous passage through skin layers made receptive by the vasodilation effect of the rubefacients.

A further factor in improved salicylate absorption might be that the polysiloxane provides a barrier overlying the applied area which retards salicylate evaporation (generally accellerated by the rubefacients) to assure proper salicylate concentration in intimate skin contact.

It has been postulated that the polysiloxane itself may pass through the skin layers which have been affected by the rubefacients and vasodilators to provide direct joint lubrication in situ.

Thus, it will be seen that there is provided a topical analgesic preparation which achieves the various objects of the invention and which is well suited to meet the conditions of practical use.

As various changes might be made in the topical analgesic preparation as above set forth, it is to be understood that all matter herein described is to' be interpreted as illustrative and not in a limiting sense.

Having thus described the invention, there is claimed as new and desired to be secured by Letters Patent:

1. An analgesic preparation suitable for use in the mitigation of pain of musculo-skeletal etiology comprising:

a. an analgesic in an amount sufficient to alleviate musculo-skeletal pain,

b. a rubefacient in an amount sufficient to provide localized heat sensation, and

c. a polysiloxane having the formula:

R R R l R Si O Si O Si R l l l R R R wherein R represents an organic radical selected from the group consisting of alkyl, aryl, alkaryl, and aralkyl, and n is an integer between 0 and 2,000, said polysiloxane having a viscosity between 50 and 200 centistokes in a range from about 10 to 40 percent by weight of the total preparation,

whereby percutaneous absorption of the analgesic is enhanced.

2. An analgesic preparation in accordance with claim 1 wherein the analgesic is a salicylate.

3. An analgesic preparation in accordance with claim 1 wherein the analgesic is selected from the group consisting of methyl salicylate, glycol monosalicylate, trithamalamine salicylate, salicylamide and dipropylene glycol salicylate.

4. An analgesic preparation in accordance with claim 1 further including a vasodilator selected from the group consisting of methacholine chloride, histamine dihydrochloride, and methyl nicotinate.

5. An analgesic preparation suitable for use in the mitigation of pain of musculo-skeletal etiology comprising:

a. an analgesic in an amount sufficient to alleviate musculo-skeletal pain,

b. a rubefacient in an amount sufficient to provide localized heat sensation, and c. a C -C dialkylpolysiloxane in a range from about 10 to 40 percent by weight of the total preparation and of a viscosity from about 50 to 200 centistokes,

whereby percutaneous absorption of the analgesic is enhanced.

6. An analgesic preparation in accordance with claim 5 wherein the dialkylpolysiloxane is dimethylpolysiloxane.

7. A method of administering treatment for the alleviation of pain of musculo-skeletal etiology, said method comprising topically applying an analgesically effective amount of the preparation of claim 1.

8. A method of administering treatment for the alleviation of pain of musculo-skeletal etiology, said method comprising topically applying an analgesically effective amount of the preparation of claim 5.

Claims (8)

1. AN ANALGESIC PREPARATION SUITABLE FOR USE IN THE MITIGATION OF PAIN OF MUSCULO-SKELETAL ETIOLOGY COMPRISING: A. AN ANALGESIC IN AN AMOUNT SUFFICIENT TO ALLEVIATE MUSCULOSKELETAL PAIN, B. A RUBEFACIENT IN AN AMOUNT SUFFICIENT TO PROVIDE LOCALIZED HEAT SENSATION, AND C. A POLYSILOXANE HAVING THE FORMULA:
2. An analgesic preparation in accordance with claim 1 wherein the analgesic is a salicylate.
3. An analgesic preparation in accordance with claim 1 wherein the analgesic is selected from the group consisting of methyl salicylate, glycol monosalicylate, trithamalamine salicylate, salicylamide and dipropylene glycol salicylate.
4. An analgesic preparation in accordance with claim 1 further including a vasodilator selected from the group consisting of methacholine chloride, histamine dihydrochloride, and methyl nicotinate.
5. An analgesic preparation suitable for use in the mitigation of pain of musculo-skeletal etiology comprising: a. an analgesic in an amount sufficient to alleviate musculo-skeletal pain, b. a rubefacient in an amount sufficient to provide localized heat sensation, and c. a C1-C6 dialkylpolysiloxane in a range from about 10 to 40 percent by weight of the total preparation and of a viscosity from about 50 to 200 centistokes, whereby percutaneous absorption of the analgesic is enhanced.
6. An analgesic preparation in accordance with claim 5 wherein the dialkylpolysiloxane is dimethylpolysiloxane.
7. A method of administering treatment for the alleviation of pain of musculo-skeletal etiology, said method comprising topically applying an analgesically effective amount of the preparation of claim 1.
8. A method of administering treatment for the alleviation of pain of musculo-skeletal etiology, said method comprising topically applying an analgesically effective amount of the preparation of claim 5.
US3880996A 1974-03-11 1974-03-11 Topical analgesic preparation and method of using Expired - Lifetime US3880996A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3880996A US3880996A (en) 1974-03-11 1974-03-11 Topical analgesic preparation and method of using

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3880996A US3880996A (en) 1974-03-11 1974-03-11 Topical analgesic preparation and method of using

Publications (1)

Publication Number Publication Date
US3880996A true US3880996A (en) 1975-04-29

Family

ID=23785401

Family Applications (1)

Application Number Title Priority Date Filing Date
US3880996A Expired - Lifetime US3880996A (en) 1974-03-11 1974-03-11 Topical analgesic preparation and method of using

Country Status (1)

Country Link
US (1) US3880996A (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2392604A1 (en) * 1977-05-31 1978-12-29 Block Drug Co Insecticides based on polysiloxane
US4324250A (en) * 1978-12-28 1982-04-13 Braun Sam M Body slenderizing method
JPS58128324A (en) * 1982-01-28 1983-07-30 Nitto Electric Ind Co Ltd Base composition and external pharmaceutical composition
US4486450A (en) * 1980-07-14 1984-12-04 Dermalogical Enterprises, Ltd. Method of treating psoriatic skin and composition
US4536404A (en) * 1983-06-16 1985-08-20 Dermatological Enterprises, Ltd. Method and composition for treating post-herpetic neuralgia
EP0288659A1 (en) * 1987-05-01 1988-11-02 Angelini Pharmaceuticals Inc. Therapeutic opthalmic compositions containing silicone polymer fluids and a process for preparing same
US4837213A (en) * 1984-09-21 1989-06-06 Centre Internatinal De Recherches Dermatologiques C.I.R.D. Pharmaceutical vehicle for active substances in the form of an anhydrous gel
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
US4931283A (en) * 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US5223257A (en) * 1992-03-11 1993-06-29 Vasu Arora Topical composition for relieving aches and pains
US5225200A (en) * 1991-09-03 1993-07-06 Gribbin Dorothea M Non-mechanical method for treating muscle contractures
US6248763B1 (en) 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US6429218B1 (en) 1997-05-19 2002-08-06 Joseph Scivoletto Method of controlling niacin concentration in lotion
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
US20060292245A1 (en) * 2005-06-23 2006-12-28 Schmit Robert G Pain relief compositions
EP1769789A2 (en) * 2005-09-30 2007-04-04 Sirton Medicare SPA Topical composition comprising capsaicin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Handbook of Non-Prescription Drugs, (1967), pp. 63-66. *
Merck Index, 7th Ed., (1960), p. 934. *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146619A (en) * 1977-05-31 1979-03-27 Block Drug Company Inc. Siloxane toxicants
FR2392604A1 (en) * 1977-05-31 1978-12-29 Block Drug Co Insecticides based on polysiloxane
US4324250A (en) * 1978-12-28 1982-04-13 Braun Sam M Body slenderizing method
US4486450A (en) * 1980-07-14 1984-12-04 Dermalogical Enterprises, Ltd. Method of treating psoriatic skin and composition
JPH031285B2 (en) * 1982-01-28 1991-01-10 Nitto Denko Corp
JPS58128324A (en) * 1982-01-28 1983-07-30 Nitto Electric Ind Co Ltd Base composition and external pharmaceutical composition
US4536404A (en) * 1983-06-16 1985-08-20 Dermatological Enterprises, Ltd. Method and composition for treating post-herpetic neuralgia
US4931283A (en) * 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4837213A (en) * 1984-09-21 1989-06-06 Centre Internatinal De Recherches Dermatologiques C.I.R.D. Pharmaceutical vehicle for active substances in the form of an anhydrous gel
US4879304A (en) * 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
EP0288659A1 (en) * 1987-05-01 1988-11-02 Angelini Pharmaceuticals Inc. Therapeutic opthalmic compositions containing silicone polymer fluids and a process for preparing same
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
US5225200A (en) * 1991-09-03 1993-07-06 Gribbin Dorothea M Non-mechanical method for treating muscle contractures
US5223257A (en) * 1992-03-11 1993-06-29 Vasu Arora Topical composition for relieving aches and pains
US6429218B1 (en) 1997-05-19 2002-08-06 Joseph Scivoletto Method of controlling niacin concentration in lotion
US6248763B1 (en) 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
US20060292245A1 (en) * 2005-06-23 2006-12-28 Schmit Robert G Pain relief compositions
US20080317873A1 (en) * 2005-06-23 2008-12-25 Epsom-It, Inc. Pain Relief Compositions
EP1769789A2 (en) * 2005-09-30 2007-04-04 Sirton Medicare SPA Topical composition comprising capsaicin
EP1769789A3 (en) * 2005-09-30 2008-07-16 Sirton Medicare SPA Topical composition comprising capsaicin

Similar Documents

Publication Publication Date Title
Dean et al. Studies on the local treatment of rabies-infected wounds
EARLE Thyroid hormone and tricyclic antidepressants in resistant depressions
US5183588A (en) Ternary system based on perfluorinated ethers
US3541205A (en) Wash resistant lotion containing organosilicon resins
Watson et al. Topical glyceryl trinitrate in the treatment of chronic anal fissure
US5827886A (en) Composition for relief of arthritis-induced symptoms
US6103245A (en) Topical barrier composition containing silicone and bentonite
US4477469A (en) Preparations containing methylsulfonylmethane and methods of use and purification
US3784684A (en) Coronary dilator in a pharmaceutical dosage unit form
US5738859A (en) Cosmetic composition
US4546112A (en) Method for preventing or reducing dipilatory irritation
US4199576A (en) Analgesic and anti-inflammatory compositions for topical application
US3965261A (en) Method for treating papillomas
US5888984A (en) Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US4256763A (en) Treatment of herpes simplex infections and acne
US4296130A (en) Methylsulfonylmethane and methods of use
US4234566A (en) Antihistamine and methods for use thereof
US4424205A (en) Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4355046A (en) Dermatologic and cosmetic ointment base
US5002974A (en) Anesthetic/skin moisturizing composition and method of preparing same
US4301145A (en) Antiseptic skin cream
US4102995A (en) Tar gel formulation
US4585656A (en) Treatment of herpes
Turley et al. Psyllium augments the cholesterol-lowering action of cholestyramine in hamsters by enhancing sterol loss from the liver
Schwartz et al. Regression of experimental hamster cancer by beta carotene and algae extracts